Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Analysis
DELISTED 2025
What happened to Sonnet BioTherapeutics Holdings, Inc. (SONN) stock?
Sonnet BioTherapeutics Holdings, Inc. (SONN) no longer trades on public markets. It was delisted in December 2025. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- December 2025
- Last recorded price (historical):
- $1.26 (last quote on record before the December 2025 delisting; historical, not a current quote)
Market cap $8.43M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Sonnet BioTherapeutics Holdings, Inc. (SONN). Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing innovative oncology therapeutics. Their lead candidate, SON-1010, targets non-small cell lung cancer and head and neck cancer.
Last analyzed: Mar 17, 2026Sonnet BioTherapeutics Holdings, Inc. (SONN) Healthcare & Pipeline Overview
More about this archive record
Can I still buy SONN shares?
No. SONN stopped trading on public markets in December 2025, so the shares are not available through a broker. Anything you see quoted for SONN elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SONN stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Sonnet BioTherapeutics Holdings, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.